menu
    • menu
    [{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA processing","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ GSK"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ Foresite Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Remix Therapeutics

    Menu

    Remix Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Remix Therapeutics

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed

                            Remix Therapeutics

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,042.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Remix Enters Collaboration with Roche for RNA Processing Modulating Therapies

                            Details : Roche will use Remix's REMaster platform to develop small molecule therapeutics modulating RNA processing, securing exclusive rights to specific targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $30.0 million

                            March 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,042.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Remix Therapeutics

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed

                            Remix Therapeutics

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : GSK

                            Deal Size : $1,045.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Dru...

                            Details : Under the terms of the agreement, Remix will receive preclinical, clinical, commercial, and sales milestone payments and tiered royalties for products. In exchange, Janssen will have exclusive rights to three specific targets with applications in immunol...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $45.0 million

                            February 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : GSK

                            Deal Size : $1,045.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Remix Therapeutics

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed

                            Remix Therapeutics

                            U.S.A arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Foresite Capital

                            Deal Size : $81.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogr...

                            Details : The funds will support development of the company’s REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 12, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Foresite Capital

                            Deal Size : $81.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth